USA Trust is the basis of any relationship, and the rare disease community is an excellent example of why transparent, constructive collaboration is essential to advancing treatments for patients Scientific advances are transforming what is possible for patients with rare diseases, yet the policies governing access to these treatments often struggle…
China CD47 is a protein that stops immune cells called macrophages from destroying healthy cells, a signal many cancers exploit to avoid immune attack. After Gilead and Pfizer spent more than 7 billion USD on CD47 programmes that failed or were discontinued, much of the industry stepped away. Dr Tian Wenzhi, founder,…
USA Samsung Bioepis is expanding in the US biosimilars market, with ten FDA approvals so far, seven assets in development, and an ambitious target of 20 products on the market by 2031. Tom Newcomer, SVP and Head of US Commercial, sets out why quality and supply reliability, rather than low prices,…
USA One of India’s leading pharmas is in transformation mode, with the US at the heart of it. Zydus, not content with staying in its lane as a pure-play generics player (among the top five in the US market), has been branching out over the past decade, with the aim of…
Europe Europe accounts for more than half of Sandoz’s global sales, and the company keeps reinvesting here, from biosimilar development and manufacturing in Slovenvia and France to antibiotic production in Austria. Christophe Delenta, President Europe, explains how closely Sandoz’s success is tied to Europe, how the company plans to grow its…
Korea We are building an end-to-end ecosystem that connects the journey from the laboratory to the patient within a unified value chain Dr Pyung-suk Ki has built Korean biotech ViGenCell around an integrated “lab to patient” model spanning cell therapy research, clinical development, and in-house manufacturing. Dr Ki discusses how his…
Europe 24 of the top 25 injectable drugs on the market rely on a BD component. This position puts the company at the centre of the GLP-1 boom, the coming biosimilars wave, and the shift of injectable treatment from hospitals to patients’ homes. Patrick Jeukenne, BD’s worldwide president of Pharmaceutical Systems,…
USA Generics and biosimilars serve as the financial bedrock preventing the US healthcare system from collapsing under the weight of escalating drug prices. “Generic drugs account for nearly 90 percent of all prescriptions filled in the United States, yet they consume only about 12 percent of total US prescription drug spending,”…
USA The American pharmaceutical market dominates the global landscape, accounting for nearly 50 percent of all global prescription drug sales by value. In 2024, the US market alone generated roughly USD 800 billion of the USD 1.7 trillion worldwide pharmaceutical revenue, cementing its status as the undisputed epicentre of the global…
USA A single pivotal trial can cost up to USD 150 million. A biosimilar efficacy study can take two to three years. A cell or gene therapy batch can be one patient’s only treatment. In 2026, along with several major personnel changes, the FDA moved to ease all three of these…
Korea When you establish an ecosystem where researchers can freely generate and test ideas, they can rapidly address critical real-world challenges At his lab in KAIST’s Department of Chemical and Biomolecular Engineering, Distinguished Professor Sang Yup Lee is pioneering microbial cell factory technologies to replace fossil-fuel-based manufacturing with sustainable biomanufacturing.…
Global After nearly two decades of real-world use, the safety and efficacy of biosimilars are no longer in question, yet access remains uneven worldwide. Following Global Biosimilars Week 2026, International Generic and Biosimilar Medicines Association (IGBA) Secretary General Ana Gaunt argues that the barriers are now policy and market design, and…
See our Cookie Privacy Policy Here